TickerFacts.

20/20 Biolabs, Inc. (AIDX): Revenue

Annual figures by period end, from SEC filings.

$2.05M
Year ended 2025-12-31
$2.04M
Trailing 12 months to 2026-06-30
2024-12-31: $1.75M2025-12-31: $2.05M$2.05M
2024-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$2.05M+16.7%2026-03-31, From 2025-01-01
2024-12-31$1.75Mn/a2026-03-31, From 2024-01-01

Revenue at similar companies

Companies with the same SEC industry code (Services-Testing Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
20/20 Biolabs, Inc. (AIDX)2025-12-31$2.05M+16.7%
iSpecimen Inc. (ISPC)2025-12-31$1.93M-79.2%
Absci Corp (ABSI)2025-12-31$2.80M-38.2%
OneMedNet Corp (ONMD)2025-12-31$1.36M+111.4%
bioAffinity Technologies, Inc. (BIAF)2025-12-31$6.16M-34.2%
Cannabis Bioscience International Holdings, Inc. (CBIH)2025-05-31$303.0K+21.8%
Foxo Technologies Inc. (FOXO)2025-12-31$16.37M+304.0%
OmniAb, Inc. (OABI)2025-12-31$18.67M-29.3%
MaxCyte, Inc. (MXCT)2025-12-31$33.03M-14.5%

Compare AIDX, ISPC, ABSI, ONMD side by side · Screen every company in Services-Testing Laboratories ↗